Transparency Market Research in its new report titled, “Tyrosine Kinase JAK Inhibitors Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the tyrosine kinase JAK inhibitors market. The TMR report anticipates that the rise in prevalence of autoimmune diseases and cancer will drive the tyrosine kinase JAK inhibitors market during the forecast period i.e, 2018-2026. Moreover, increased application of JAK inhibitors in inflammatory diseases and increase in investment from pharmaceutical companies are some other drivers of the tyrosine kinase JAK inhibitors market. However, stringent government regulations, high cost of treatment, and lack of funds for conducting research are likely to hamper the market during the forecast period, says the report.
According to the report, tyrosine kinases are enzymes capable of transferring the phosphate group from ATP (adenosine triphosphate) to a cellular protein. They function as an on or off switch for several cellular mechanisms. On the protein, the phosphate group is affiliated to the tyrosine amino acid. Tyrosine kinases are a subclass of the larger group of protein kinases that connect phosphate groups to extra amino acids (threonine and serine). In interconnecting signals in a cell (signal transduction) and cellular activities such as cell division regulation, proteins phosphorylation is an important mechanism, which is performed by kinases. The TMR report has segmented the global tyrosine kinase JAK inhibitors market based on type, application, and region. In terms of type, the tyrosine kinase JAK inhibitors market is classified into tofacitinib, ruxolitinib, and baricitinib. On the basis of application, the tyrosine kinase JAK inhibitors market is categorized into rheumatoid arthritis (RA), polycythemia vera (PCV), myelofibrosis (MF), and others.
On a geographical standpoint, the global tyrosine kinase JAK inhibitors market is split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, North America is expected to dominate the global tyrosine kinase JAK inhibitors market due to availability of advanced medications and increased health expenses. Awareness among the people about diseases is also a major factor boosting the market in the region. The tyrosine kinase JAK inhibitors market in Asia Pacific is expected to expand at a rapid pace owing to increase in prevalence of cancer and autoimmune diseases. Lack of awareness about diseases and unavailability of advanced medication and treatment in underdeveloped countries such as Lebanon, Syria, Cyprus, Turkey, and Iraq are likely to restrain the tyrosine kinase JAK inhibitors market in Middle East & Africa. Some of the major players operating in the global market of tyrosine kinase JAK inhibitors are profiled in this report to give a better competitive analysis of the market and these include Pfizer Inc., Incyte Corporation, Novartis AG, Eli Lilly and Company, Gilead, Sanofi, Galapagos NV, AbbVie Inc., Vertex Pharmaceuticals Incorporated, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., CELGENE CORPORATION, and CTI BioPharma Corp. among others.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453